TrialArthritis and rheumatism2012

N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial.

Zhi-Wei Lai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.